Full-Time

Vice President/Senior Vice President

Quality

Posted on 5/1/2024

Editas Medicine

Editas Medicine

201-500 employees

Develops CRISPR-based gene editing medicines

Biotechnology

Senior

Cambridge, MA, USA

Required Skills
Google Cloud Platform
Requirements
  • Bachelor’s degree required
  • 20 or more years of cGxP experience preferred
  • Experience with cell and/or gene therapy products
  • Strong knowledge in analytical methodologies and technologies
  • Strong knowledge of global regulations and guidelines (EU, U.S., Japan)
  • Previous experience with clinical and commercial manufacturing
  • Experience with BLA/MAA filings and subsequent inspections
  • Proven ability to work independently and in a team-oriented environment
Responsibilities
  • Drive the strategic development and execution of GxP Quality Management System
  • Promote a culture of quality and continuous improvements
  • Lead GxP teams across multiple sites
  • Ensure company-wide adherence to GMP, GCP, GTP, GLP, GDP regulations
  • Provide strong leadership in troubleshooting and complex problem solving
  • Interact professionally with company management and third parties
  • Own the Quality Risk Management, Quality Council, and Management Review programs
  • Ensure a constant state of Inspection Readiness
  • Manage budget and resources in alignment with program timelines
  • Author and review regulatory filings (e.g., IND, IMPD, BLA, MAA)

Editas Medicine specializes in CRISPR gene editing technologies, including CRISPR/Cas9 and CRISPR/Cas12a, to create groundbreaking treatments for serious diseases. This company offers a technologically advanced environment where employees can contribute to pioneering efforts in medical science. Working here provides a unique opportunity to engage in impactful research and development that could potentially improve the lives of people worldwide.

Company Stage

IPO

Total Funding

$884.6M

Headquarters

Cambridge, Massachusetts

Founded

2013

Growth & Insights
Headcount

6 month growth

11%

1 year growth

24%

2 year growth

14%
INACTIVE